| Literature DB >> 29654101 |
Julie E Stein1, Jeffrey Patterson-Fortin1, Benjamin E Bodnar1.
Abstract
A 44-year-old woman with cutaneous psoriasis and no history of joint involvement recently treated with adalimumab was admitted to the inpatient Internal Medicine service for uncontrolled, severe joint pain so debilitating that it limited her activities of daily living and prevented her from working as a medical technologist. She had stopped taking adalimumab 3 weeks prior to presentation after receiving approximately 2.5 months of therapy for cutaneous psoriasis unresponsive to trials of topical steroids and methotrexate. Antinuclear antibody and anti-double-stranded DNA antibodies were positive at high titres. She received a course of oral corticosteroids with improvement in her symptoms. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.Entities:
Keywords: dermatology; immunological products and vaccines; musculoskeletal syndromes; systemic lupus erythematosus
Mesh:
Substances:
Year: 2018 PMID: 29654101 PMCID: PMC5905774 DOI: 10.1136/bcr-2017-223473
Source DB: PubMed Journal: BMJ Case Rep ISSN: 1757-790X